Core Viewpoint - The Hong Kong stock market is experiencing fluctuations after a period of growth, leading investors to question whether this is a signal of a market end or an opportunity for re-entry. Current market conditions suggest that the pullback may not be a terminal point but rather a wait for several key opportunities to become clearer [1] Group 1: Valuation and Market Position - Despite a previous rally that has repaired valuations, the Hong Kong stock market remains at historically low levels compared to major overseas technology indices. As of January 21, 2026, the price-to-earnings ratio (PE-TTM) of the Hong Kong technology sector is significantly lower than that of the Nasdaq, indicating a medium to long-term safety margin and allocation value. The pullback may provide a more suitable entry point for investors [2] Group 2: AI and Technological Advancements - The recent advancements in the AI sector, particularly with domestic large model companies listing in Hong Kong, are providing sustained momentum for the technology sector. For instance, the "Qianwen App" achieved over 100 million monthly active users within two months of launch, and AI motion control technologies are generating significant interest overseas. This indicates that the commercialization of AI technology is accelerating, and while short-term market sentiment may fluctuate, the logic of value reassessment driven by AI remains unchanged [3] Group 3: Sectoral Support and Opportunities - Beyond AI, several industries within the Hong Kong market exhibit strong support: - New Consumption: Leading companies in trendy toys, tea drinks, and jewelry are expected to drive value reassessment due to explosive performance and emotional premium - Innovative Pharmaceuticals: Chinese innovative pharmaceutical companies are accelerating their international expansion, with large orders expected to improve profitability - New Energy: Policies aimed at reducing competition are gradually being implemented, which may optimize the supply-demand landscape in the industry - Technology: The expansion of computing power demand and the acceleration of large model commercialization are creating abundant opportunities across the industry chain [4] Group 4: Signals to Watch - The current pullback in the Hong Kong stock market is, to some extent, waiting for the confirmation of the following signals: - AI application performance realization: Whether the technology can truly translate into corporate profits - Overseas liquidity and risk appetite: The willingness of global funds to allocate to emerging markets - Corporate earnings recovery rhythm: Particularly whether first-quarter earnings can support valuations [5] Group 5: Investor Strategy - For ordinary investors, it is advisable not to be overly pessimistic during the pullback. Gradual accumulation in the low valuation range may be beneficial. Additionally, a long-term perspective is essential, as the Hong Kong market is characterized by significant volatility, requiring patience to seize structural market opportunities [6]

Market Overview - Global markets showed mixed performance, with the Hang Seng Index closing at 26,750, up 0.45% year-to-date, while the US Dow Jones fell by 0.58% [1][3] - The Chinese stock market saw gains, particularly in materials, consumer discretionary, and healthcare sectors, while energy and real estate lagged [3] Industry Insights - The Chinese pharmaceutical sector is experiencing a significant upward trend, with the MSCI China Healthcare Index rising 9.2% since early 2026, outperforming the MSCI China Index by 5.6% [4] - The trend of Chinese innovative drugs going overseas continues to gain momentum, with multiple business development (BD) transactions occurring in early 2026, indicating a strong market for overseas licensing [5] - Key transactions include the overseas rights granted by Rongchang Biopharma to AbbVie for RC148 and by Haisika for HSK39004, showcasing the clinical progress of these drugs [5] Company Analysis - China Ping An is projected to see a 12% increase in operating profit to RMB 135.9 billion in 2025, driven by improvements in life and health insurance segments [7] - The new business value (NBV) is expected to grow by 42% year-on-year to RMB 40.4 billion, with a strong performance anticipated in the first quarter of 2026, particularly in the bancassurance channel [8] - The target price for China Ping An has been raised to HKD 90, reflecting adjustments in profit and NBV growth forecasts, with the company currently trading at 0.71 times FY26E P/EV [8]

具体来看，CXO、创新药等概念集体下挫，晶泰控股、三生制药、微创机器人、药明合联、药明生 物、信达生物等领跌。 招商国际表示，在2025年创新药BD出海授权交易爆发式增长的基础上，2026年初已经有多个BD落地， 体现了中国创新药出海授权交易较高的景气度。 港股市场再度震荡调整，医药板块领跌，恒生生物科技指数跌超2%，聚焦创新药产业的恒生医药ETF （159892）、聚焦CXO+AI医疗的港股通医疗ETF（520510）均跌超2%。 ...

Summary of Conference Call Industry Overview - The conference focused on updates and developments in the Chinese biopharmaceutical industry, particularly highlighting companies such as BeiGene, 3SBio, and Kelun-Biotech [1][10]. Key Company Insights BeiGene - BeiGene's BCL-2 inhibitor has been approved for sale in China and is expected to receive accelerated approval in the U.S. within the year [1]. - BCL-2 is viewed as a second growth driver for BeiGene, complementing its existing BTK inhibitors, which have shown rapid sales growth in the U.S. market [2]. - The company has a robust pipeline for solid tumors, with several candidates entering late-stage development, including treatments for breast cancer and other indications [3]. - BeiGene is anticipated to report its first annual profit, with expectations that its annual report may exceed forecasts [3]. 3SBio - Pfizer has outlined a global development plan for its drug 707, with five global Phase III trials expected to start by 2026, targeting various cancers [4]. - The trials include first-line treatments for colorectal cancer and non-small cell lung cancer [4]. Kelun-Biotech - Kelun-Biotech is expected to have a significant year with five products anticipated to be commercialized, three of which have already been included in the national medical insurance [5]. - The company has successfully commercialized its top two ADC products and is expected to see explosive growth following their inclusion in insurance [5]. Innovent Biologics - Innovent's Ivosidenib is expected to receive final approval from the FDA in Q4 of this year, with ongoing clinical trials for various cancers [6][7]. - The company is also preparing for the commercialization of its CAR-T product, which has already been approved domestically [8]. Rongchang - Rongchang has announced plans for three Phase III trials, including one for non-small cell lung cancer, which has received FDA approval [7][8]. Other Notable Mentions - Merck has initiated 16 global Phase III trials for its drug targeting various major indications, with data expected in the second half of the year [5]. - The conference highlighted the importance of clinical trial data releases for several companies, which are crucial for their long-term valuations [3][10]. Market Dynamics - The overall market for innovative drugs is currently experiencing a downturn, primarily due to internal funding shifts within the pharmaceutical sector [10]. - The high percentage of holdings in innovative and traditional pharmaceuticals (around 75%) has led to a reallocation of funds towards other sectors like AI healthcare and CROs [11]. - Despite the market's performance, the fundamental aspects of many companies remain strong, with ongoing clinical advancements and positive earnings expectations [11]. - The total amount of business development (BD) transactions in recent weeks has already reached 25% of last year's total, indicating a robust pace of international expansion [11]. Conclusion - The conference provided a comprehensive overview of the current state of the biopharmaceutical industry in China, highlighting significant advancements and the potential for growth among key players. The market dynamics suggest a temporary disconnect between stock performance and fundamental company health, indicating potential investment opportunities.

1月26日，必贝特涨5.02%，截至发稿，报57.08元/股，成交7102.99万元，换手率2.78%，总市值256.88 亿元。 资料显示，广州必贝特医药股份有限公司位于广东省广州市高新技术产业开发区科学城崖鹰石路25号 A-3栋第七层、第八层，成立日期2012年1月19日，上市日期2025年10月28日，公司主营业务涉及创新 药自主研发。 截至发稿，李俊累计任职时间8年49天，现任基金资产总规模956.67亿元，任职期间最佳基金回报 146.12%， 任职期间最差基金回报-39.56%。 声明：市场有风险，投资需谨慎。 本文基于第三方数据库自动发布，任何在本文出现的信息（包括但 不限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成个人投资建 议。受限于第三方数据库质量等问题，我们无法对数据的真实性及完整性进行分辨或核验，因此本文内 容可能出现不准确、不完整、误导性的内容或信息，具体以公司公告为准。如有疑问，请联系 biz@staff.sina.com.cn。 责任编辑：小浪快报 数据显示，华夏基金旗下1只基金重仓必贝特。华夏中证光伏产业ETF发起式联接A（012885）四季度持 ...

Group 1 - The overall market trend for 2026 is expected to be optimistic, driven by a combination of fundamental, liquidity, sentiment, and policy factors [1][2] - China's GDP has surpassed 140 trillion, indicating a strong economic achievement that supports market performance [1] - Despite a recent cooling in market sentiment, the overall bullish sentiment remains high, and the market is currently undergoing a necessary adjustment phase [2] Group 2 - Historical analysis shows that previous bull markets have been characterized by short bursts of activity followed by long periods of adjustment, which negatively impacted investor experiences [3] - The current market environment is being guided towards healthier long-term development through measures such as increased margin requirements and regulatory support [4] - The AI sector remains a key focus for 2026, with strong growth expected in upstream computing power and semiconductor equipment due to expansion and rising demand [5][6] Group 3 - The innovative drug sector is projected to continue its growth trajectory in 2026, focusing on new drug platforms and expanding applications for existing treatments [6]

Investment Rating - The investment rating for the pharmaceutical industry is "Positive" (maintained) [4] Core Insights - The report highlights the potential acceleration of the surgical robot industry following the release of the service pricing guidelines by the National Medical Insurance Administration, which clarifies the pricing structure for surgical robot services and consumables [3][18] - The report emphasizes the importance of innovation in the pharmaceutical sector, noting that the industry has completed a transition from old to new growth drivers, particularly in innovative drugs, which are expected to continue to perform well in 2026 [46][47] - The report suggests a focus on sectors such as innovative drugs, AI medical technology, and brain-computer interfaces, which are anticipated to see significant advancements in 2026 [46][48] Summary by Sections Market Performance - From January 19 to January 23, the pharmaceutical index decreased by 0.39%, with an excess return of 0.23% relative to the CSI 300 index. The market was relatively stable, with a notable increase of 1.26% on Friday, driven by themes like brain-computer interfaces and AI medical technology [5][27] - A total of 330 stocks rose while 137 fell during the week, with notable gainers including *ST Changyao (+70.37%) and Hualan Biological (+32.21%) [27][28] Surgical Robot Industry - The surgical robot market is expected to benefit from the new pricing guidelines, which will enhance the clinical application of surgical robots and promote a sustainable business model [3][18] - The domestic laparoscopic robot market is projected to grow significantly, with a compound annual growth rate (CAGR) of 29.3% from 2024 to 2030 [9][15] Investment Recommendations - The report recommends focusing on strong fundamentals and well-adjusted innovative drug stocks, including companies like Xinlitai, Zexing Pharmaceutical, and Hengrui Medicine, as well as medical technology firms like Yuyue Medical and Alibaba Health [5][49] - It also suggests monitoring companies involved in the export of CXO services and those with stable operations and low valuations that are expected to see fundamental changes in 2026 [5][46] Future Outlook - The report anticipates that the pharmaceutical industry will continue to improve marginally in 2026, driven by technological innovation and performance recovery in traditional sectors [46][47] - Key areas of focus include innovative drugs, AI medical technology, and the aging population's healthcare needs, which are expected to drive demand [46][48]

Core Viewpoint - The report from CITIC Securities indicates that while industrial production remains resilient and exports are growing rapidly, domestic demand indicators such as consumption and investment are still weak, highlighting a characteristic of "strong production versus weak demand" throughout the previous year [1] Economic Environment - The current macroeconomic environment shows similarities to the investment peak period of 2020-2021, with interbank interest rates at their lowest levels since 2020 [1] - The combination of weak macro demand and loose liquidity is expected to favor structural investment opportunities in certain sectors [1] Sector Insights - In the technology sector, AI semiconductors and new energy are identified as the core areas of current prosperity, with strong policy support for AI applications and accelerated commercialization [1] - The global capacity planning for space photovoltaics has exceeded expectations, and technological breakthroughs are opening up trillion-dollar markets [1] - The innovative drug sector is seeing value realization driven by business development transactions, clinical breakthroughs, and new drug approvals [1] Resource Sector - The non-ferrous metals industry has the highest forecasted performance improvement rate for 2025, with attention on the subsequent transmission of prosperity to the energy and machinery sectors [1] - As monetary easing continues, funds are expected to gradually shift from the financial system to the real economy, benefiting sectors such as non-ferrous metals, chemicals, machinery, and consumer goods [1] - Since December 2025, the South China Metal Index has risen by 12.5%, while the energy and industrial product indices have only increased by around 7%, suggesting better investment value in the current market [1]

围绕新"新三样"，新政策举措接连落地。 先说机器人。北京近日首设机器人专业职称，7月将启动首次评审，为的是让人才需求跟上产业热度。 上海海关为机器人上"户口"，以精准统计更好支持行业发展。从蹒跚起步到奔跑赛场、腾空起舞，机器 人加速进化。 数据来源：国家统计局等 体"。新一批在全国复制推广的25项跨境贸易便利化措施公布，支持"空中丝绸之路"发展等。政策因时 而动、因势而变，护航经济大船行稳致远。 快中有慢，方显定力。抢位更要错位，才能在空间坐标中找准接口，各展所长。 找准自身优势和全国大局的接口，在深度参与全国统一大市场建设中大展身手。追"新"，不是不顾实 际、盲目追风口，而是立足地区差异性，以一域之特色服务全局之所需。广东深圳依托珠三角制造业集 群优势，在具身智能产业上投早、投小、投硬科技。重庆人工智能湾区建设启动，发布"渝车出海"等12 个案例。这启示我们，只有正视客观差别，厚植特色优势，才能杜绝贪大求全，找准向新发展的赛 道，"既为一域争光、更为全局添彩"。 找准接口，顺势而为。4部门推进职业技能证书互通互认，促进技能人才合理顺畅流动。商务部部署健 全现代市场和流通体系，完善现代商贸流通体系。借助全国统 ...

Macro and Strategy Research - The US economy shows strong internal momentum with a 0.3% month-on-month increase in personal consumption expenditures adjusted for inflation in November 2025, marking the highest growth rate since the second half of 2025 [2] - In Europe, inflation dropped below 2% year-on-year in December 2025, indicating easing pressure, supported by labor costs and year-end consumption [3] - Domestic economic growth in China for 2025 is expected to meet targets despite a slowdown in the fourth quarter, with net exports providing structural support in early 2026 [3] Fixed Income Research - The bond market continues to show signs of recovery, with mid- to long-term bonds performing well, driven by a strong equity market and manageable bank liability pressures [5][7] - The issuance of special bonds increased significantly, with a total of 56 bonds issued, amounting to 619.1 billion yuan during the reporting period [7] - The overall bond market is characterized by a recovery trend, with the yield on 7-year government bonds declining the most [7] Industry Research - Nine departments in China have issued opinions to promote high-quality development in the pharmaceutical retail industry, indicating potential benefits for leading chain pharmacies and an expected operational turning point [10][12] - The SW pharmaceutical industry index shows a price-to-earnings ratio of 52.01, with a valuation premium of 266% relative to the CSI 300 index [11] - The report suggests focusing on investment opportunities in innovative drugs, CXO, and upstream life sciences, while also monitoring segments like small nucleic acids [12]